Luke, J. J., Fong, L., Chung, K., Tolcher, A. W., Kelly, K., Hollebecque, A., … Barlesi, F. (2019). Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. In ANNALS OF ONCOLOGY (Vol. 30). Barcelona, SPAIN: OXFORD UNIV PRESS.

Luke, J. J., L. Fong, K. Chung, A. W. Tolcher, K. Kelly, A. Hollebecque, C. Le Tourneau, et al. “Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours.” In ANNALS OF ONCOLOGY, Vol. 30. OXFORD UNIV PRESS, 2019.

Luke JJ, Fong L, Chung K, Tolcher AW, Kelly K, Hollebecque A, et al. Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.

Luke, J. J., et al. “Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours.” ANNALS OF ONCOLOGY, vol. 30, OXFORD UNIV PRESS, 2019.

Luke JJ, Fong L, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier P, Khasraw M, Allaire K, Fan F, Fang H, Patel M, Henner W, Hayflick J, McDevitt M, Barlesi F. Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.